OR WAIT 15 SECS
ReForm Biologics and KBI Biopharma will collaborate to improve biopharmaceutical formulations and development.
On April 4, 2018, ReForm Biologics and KBI Biopharma announced a partnership to improve biopharmaceutical formulations and development.
The companies report that this collaboration will help customers extend product lifecycles, enable improved dosing for patients, and enhance manufacturing efficiencies. As part of the partnership, KBI has made an equity investment in ReForm Biologics.
According to ReForm, its proprietary excipient technologies decrease viscosity and enhance stability, thus enabling subcutaneous and improved device-assisted administration that can enable biopharmaceutical companies to extend product lines. The company expects that this product-line extension can expand market share and maximize value creation.
KBI will provide services to ReForm to further develop and validate its biologic formulation platform while also gaining access to ReForm’s proprietary technology. Reform will maintain the ability to use its formulation technologies directly with its pharmaceutical and biotechnology partners. Financial terms of the agreement were not disclosed.
“We are very excited to collaborate with ReForm and leverage their enabling formulation technology to advance the programs of our client partners,” said Tim Kelly, PhD, president and CEO of KBI, in a company press release. “KBI has a long-standing track record of leadership in the formulation of biologics, and ReForm’s unique technology will help us address some of the biggest challenges in protein formulation. Together, KBI and ReForm will help transform our clients’ most innovative pipeline discoveries into viable commercial products to treat patients.”
“This collaboration brings together ReForm’s innovative formulation platforms with KBI’s deep industry experience and global customer base,” said John M. Sorvillo, PhD, CEO at ReForm, in the release. “Access to KBI’s services and customers will allow us to advance our technologies more rapidly and generate additional revenues for both companies. We are pleased to have KBI as a shareholder and strategic partner as we expand our transformative platforms for biotherapeutic formulations, for the benefit of patients.”